stockrowTransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −31.0%
- Free cash flow
- −55.4%
- Total debt
- −89.3%
Quarter to September 2026, against a year earlier
Follow TMDX
Alert me
TransMedics Group, Inc. (TMDX) Return on equity
TransMedics Group, Inc.'s return on equity over the twelve months to 30 September 2026 was 31.9%, down 22.4 percentage points from fiscal 2025 (54.2%). Over the past ten years it has ranged from −51.5% (fiscal 2021) to 54.2% (fiscal 2025) — the current reading is the highest in ten years. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 54.2% | 34.85 |
| FY2024 | 19.4% | 34.81 |
| FY2023 | −15.4% | 12.97 |
| FY2022 | −28.4% | 23.10 |
| FY2021 | −51.5% | (15.22) |
| FY2020 | −36.3% | (85.03) |
| FY2019 | 48.8% | 35.60 |
| FY2018 | 13.2% | 1.62 |
| FY2017 | 11.5% | 11.54 |
| FY2016 | 0.00% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| TMDX TransMedics Group, Inc. | 31.9% |
| INSP Inspire Medical Systems, Inc. compare | 13.5% |
| UFPT UFP Technologies, Inc. compare | 0.00% |
| NEOG Neogen Corporation compare | −2.67% |
| AXGN AxoGen, Inc. compare | −10.4% |
| BFLY Butterfly Network, Inc. compare | −27.7% |
| NVCR NovoCure Limited compare | −35.2% |
| ALMR Alamar Biosciences, Inc. compare | −64.5% |
| ESTA Establishment Labs Holdings Inc. compare | −175.3% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on TMDX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement